Alessandro Rambaldi to Myeloproliferative Disorders
This is a "connection" page, showing publications Alessandro Rambaldi has written about Myeloproliferative Disorders.
Connection Strength
2.482
-
Long-term follow-up of recovered MPN patients with COVID-19. Blood Cancer J. 2021 06 16; 11(6):115.
Score: 0.630
-
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021 02; 35(2):485-493.
Score: 0.612
-
Inflammation and myeloproliferative neoplasms. J Autoimmun. 2017 Dec; 85:58-63.
Score: 0.479
-
Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue. Expert Rev Hematol. 2013 Aug; 6(4):429-39.
Score: 0.365
-
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Blood Cancer J. 2021 02 04; 11(2):21.
Score: 0.154
-
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia. 2018 05; 32(5):1200-1210.
Score: 0.125
-
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. J Hematol Oncol. 2017 02 22; 10(1):54.
Score: 0.117